FDA grants full approval to Bayer's Vitrakvi for NTRK fusion-positive solid tumors in adults and children. Clinical trials show a 60% overall response rate and median response duration of 43.3 months ...
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today initiation of a Phase I clinical trial with 225 Ac-GPC3 (BAY 3547926), an investigational targeted alpha radiopharmaceutical being developed to ...
Jarell Quansah has completed his move from Liverpool to Bayer Leverkusen on a five-year deal through to 2030. Liverpool say the deal is worth £30million and will include a buy-back option for the ...
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Study Overview: Regeneron Pharmaceuticals ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback